The questions of drugs, real and spurious, has come up in the healthcare sector this week, with reports of drugs not meeting quality standards, pharmaceutical companies claiming that these drugs were ...

Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care ...

The sickle cell treatment voxelotor (Oxbryta) has been withdrawn from all markets by the manufacturer Pfizer after a “higher than anticipated” number of deaths were reported and clinical evidence ...

Pfizer recalled Oxbryta and ended clinical trials over safety concerns, but sickle cell advocates are warning that stopping the drug abruptly could be dangerous.

Healthcare professionals have been urged to stop supplying Oxbryta “immediately” after new data revealed “an unfavourable imbalance” of “fatal events” and “acute painful crises” in patients on the ...

Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.